Compare TXT & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXT | IONS |
|---|---|---|
| Founded | 1923 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 11.8B |
| IPO Year | 1994 | 1996 |
| Metric | TXT | IONS |
|---|---|---|
| Price | $91.12 | $73.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 22 |
| Target Price | ★ $97.45 | $85.91 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | 18.01 | ★ 21.71 |
| EPS | ★ 5.11 | N/A |
| Revenue | ★ $14,799,000,000.00 | N/A |
| Revenue This Year | $5.89 | N/A |
| Revenue Next Year | $4.51 | $64.88 |
| P/E Ratio | $17.78 | ★ N/A |
| Revenue Growth | ★ 8.01 | N/A |
| 52 Week Low | $57.70 | $23.95 |
| 52 Week High | $101.57 | $86.74 |
| Indicator | TXT | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 41.30 |
| Support Level | $78.05 | $70.32 |
| Resistance Level | $91.22 | $74.42 |
| Average True Range (ATR) | 2.18 | 2.02 |
| MACD | -0.38 | -0.12 |
| Stochastic Oscillator | 44.54 | 46.92 |
Textron is a conglomerate that designs, manufactures, and services a range of specialty aircraft including small jets, propeller-driven airplanes, helicopters, and tilt-rotor aircraft. Textron Aviation manufactures and services Cessna and Beechcraft planes. Bell is a helicopter and tilt-rotor manufacturer and servicer for both commercial and military customers. Textron Systems produces uncrewed aircraft and armored vehicles for the military market as well as aircraft simulators and training for the commercial and military markets. Textron Industrial contains the Kautex business, which manufactures plastic fuel tanks for conventional and hybrid motor vehicles, and other subsidiaries that produce specialized vehicles such as golf carts and all-terrain vehicles.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).